155 related articles for article (PubMed ID: 31139323)
1. Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma.
Dulmage BO; Akilov O; Vu JR; Falo LD; Geskin LJ
Oncotarget; 2019 May; 10(33):3104-3113. PubMed ID: 31139323
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
[TBL] [Abstract][Full Text] [Related]
3. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
4. TOX expression in cutaneous T-cell lymphomas: an adjunctive diagnostic marker that is not tumour specific and not restricted to the CD4(+) CD8(-) phenotype.
Schrader AM; Jansen PM; Willemze R
Br J Dermatol; 2016 Aug; 175(2):382-6. PubMed ID: 26931394
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of TOX by skin-infiltrating T cells in Sézary syndrome and erythrodermic dermatitis.
Boonk SE; Çetinözman F; Vermeer MH; Jansen PM; Willemze R
J Cutan Pathol; 2015 Sep; 42(9):604-9. PubMed ID: 25777533
[TBL] [Abstract][Full Text] [Related]
6. TOX Expression in Mycosis Fungoides and Sezary Syndrome.
Pileri A; Cavicchi M; Bertuzzi C; Righi S; Zengarini C; Sabattini E; Roncador G; Agostinelli C
Diagnostics (Basel); 2022 Jun; 12(7):. PubMed ID: 35885488
[TBL] [Abstract][Full Text] [Related]
7. Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3.
Booken N; Gratchev A; Utikal J; Weiss C; Yu X; Qadoumi M; Schmuth M; Sepp N; Nashan D; Rass K; Tüting T; Assaf C; Dippel E; Stadler R; Klemke CD; Goerdt S
Leukemia; 2008 Feb; 22(2):393-9. PubMed ID: 18033314
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of RUNX3/p46 Promotes Cutaneous T-Cell Lymphoma.
Haider A; Steininger A; Ullmann R; Hummel M; Dimitrova L; Beyer M; Vandersee S; Lenze D; Sterry W; Assaf C; Möbs M
J Invest Dermatol; 2016 Nov; 136(11):2287-2296. PubMed ID: 27377697
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
10. Transcriptome analysis of Sézary syndrome and lymphocytic-variant hypereosinophilic syndrome T cells reveals common and divergent genes.
Moerman-Herzog AM; Acheampong DA; Brooks AG; Blair SM; Hsu PC; Wong HK
Oncotarget; 2019 Aug; 10(49):5052-5069. PubMed ID: 31489115
[TBL] [Abstract][Full Text] [Related]
11. BCL2 and JUNB abnormalities in primary cutaneous lymphomas.
Mao X; Orchard G; Lillington DM; Child FJ; Vonderheid EC; Nowell PC; Bagot M; Bensussan A; Russell-Jones R; Young BD; Whittaker SJ
Br J Dermatol; 2004 Sep; 151(3):546-56. PubMed ID: 15377339
[TBL] [Abstract][Full Text] [Related]
12. TOX expression in cutaneous B-cell lymphomas.
Schrader AM; Jansen PM; Willemze R
Arch Dermatol Res; 2016 Aug; 308(6):423-7. PubMed ID: 27180090
[TBL] [Abstract][Full Text] [Related]
13. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
14. Regulation of T-plastin expression by promoter hypomethylation in primary cutaneous T-cell lymphoma.
Jones CL; Ferreira S; McKenzie RC; Tosi I; Caesar JA; Bagot M; Whittaker SJ; Mitchell TJ
J Invest Dermatol; 2012 Aug; 132(8):2042-9. PubMed ID: 22495182
[TBL] [Abstract][Full Text] [Related]
15. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells.
Lee SH; Kim J; Kim WH; Lee YM
Oncogene; 2009 Jan; 28(2):184-94. PubMed ID: 18850007
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients.
Kohnken R; Kodigepalli KM; Mishra A; Porcu P; Wu L
Leuk Res; 2017 Jan; 52():58-66. PubMed ID: 27889686
[TBL] [Abstract][Full Text] [Related]
17. Morpholino antisense oligonucleotide-mediated gene knockdown during thymocyte development reveals role for Runx3 transcription factor in CD4 silencing during development of CD4-/CD8+ thymocytes.
Ehlers M; Laule-Kilian K; Petter M; Aldrian CJ; Grueter B; Würch A; Yoshida N; Watanabe T; Satake M; Steimle V
J Immunol; 2003 Oct; 171(7):3594-604. PubMed ID: 14500656
[TBL] [Abstract][Full Text] [Related]
18. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
19. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
[TBL] [Abstract][Full Text] [Related]
20. RUNX3 protein is overexpressed in human epithelial ovarian cancer.
Nevadunsky NS; Barbieri JS; Kwong J; Merritt MA; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2009 Feb; 112(2):325-30. PubMed ID: 18937968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
